Found: 11
Select item for more details and to access through your institution.
Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 7, p. 1770, doi. 10.1111/dom.13267
- By:
- Publication type:
- Article
Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1321, doi. 10.1111/dom.13224
- By:
- Publication type:
- Article
Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 4, p. 812, doi. 10.1111/dom.13152
- By:
- Publication type:
- Article
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 453, doi. 10.1111/dom.13079
- By:
- Publication type:
- Article
Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 77, doi. 10.1111/dom.13038
- By:
- Publication type:
- Article
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 6, p. 874, doi. 10.1111/dom.12898
- By:
- Publication type:
- Article
Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 3, p. 498, doi. 10.1111/bcp.12380
- By:
- Publication type:
- Article
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
- Published in:
- Cardiovascular Diabetology, 2016, v. 15, p. 1, doi. 10.1186/s12933-016-0407-4
- By:
- Publication type:
- Article